Imunon Stock Forum

$Imunon (IMNN.US)$
Can IMUNON's Immunotherapy Transform Ovarian Cancer Treatment? Phase 3 Trial Coming After 13-Month Survival Advantage

$Imunon (IMNN.US)$
IMUNON Reports 2024 Financial Results and Provides Business Update Highlighting Significant Progress Towards the Initiation of a Pivotal Phase 3 Study
Positive
First immunotherapy showing clinical benefits in ovarian cancer survival
13-month overall survival benefit in Phase 2 trial
Improved hazard ratio from 0.74 to 0.69
62% of long-term survivors from IMNN-001 treatment arm
Positive FDA feedback for Phase 3 trial advancement
9% decrease in operating expenses
Negative
Net...

$Imunon (IMNN.US)$ Imunon FY 2024 GAAP EPS $(1.62) Beats $(1.69) Estimate. Cash And Equivalents $5.9M
Imunon (NASDAQ:IMNN) reported quarterly losses of $(1.62) per share which beat the analyst consensus estimate of $(1.69) by 4.14 percent. This is a 25 percent increase over losses of $(2.16) per share from the same period last year.

$Imunon (IMNN.US)$
Can IMUNON's DNA Vaccine Outperform mRNA COVID Shots? New Clinical Data Reveals Key Advantages

$Imunon (IMNN.US)$ Reuters· 1 min ago
Imunon Announces New Immunogenicity Data From Phase 1 Clinical Trial of Its DNA Vaccine in Treatment of Covid-19

$Imunon (IMNN.US)$
IMUNON Announces New Immunogenicity Data from Phase 1 Clinical Trial of Its DNA Vaccine in Treatment of COVID-19
Wednesday, 26th February at 8:05 am
Results of IMNN-101 Proof-of-Concept study demonstrate persistent immunogenicity in trial participants and further validate PlaCCine® technology
IMNN-101 induced 2- to 4-fold increase in neutralizing antibody (NAb) titers from baseline through Week 4
IMNN-101 continues to show an acceptable safety profile
LAWRENCEVILLE, N.J...

$Imunon (IMNN.US)$
The translational data from IMUNON's OVATION 2 Study reveals several critical insights into IMNN-001's mechanism of action and therapeutic potential. The 20% increase in IL-12 levels with the higher dose (100mg/m2) is particularly significant, as IL-12 is a important cytokine that enhances anti-tumor immune responses. The localized effect in the peritoneal cavity, with minimal systemic presence, suggests an optimal therapeutic window that maximizes effi...

$Imunon (IMNN.US)$
Ovarian Cancer Breakthrough? New Drug Shows 13-Month Survival Advantage in Clinical Trial

$Imunon (IMNN.US)$ IMUNON Announces Translational Data from Phase 1/2 OVATION 2 Study of IMNN-001 in Advanced Ovarian Cancer
1 MINUTE AGO, 8:05 AM EST
VIA GLOBENEWSWIRE
Data reinforce dose-dependent mechanism with IMNN-001 100mg/m2 dose associated with 20% increase in IL-12 levels compared to 79mg/m2 dose
Results from OVATION 2 Study continue to validate TheraPlas® technology, demonstrating DNA-mediated production of key anti-cancer immune cytokines following treatment
IMNN-001 continues ...

$Imunon (IMNN.US)$
Oncology Veteran Takes Helm at IMUNON as Phase 3 Trial Approaches - Key Details